BIVI - BioVie initiated with an overweight at Cantor Fitzgerald
- Cantor Fitzgerald analyst Charles Duncan initiated coverage of BioVie ( BIVI ) with an Overweight rating and $7 price target.
- The company's development strategy is based on research that suggests that neuroinflammation is a primary driver of disease progression, and believes NE3107 can be broadly applicable in a range of neurological disease settings, Duncan tells investors.
- BioVie 's SA Quant Rating says Strong Sell whereas, Wall St. Analysts Rating stands with Strong Buy (3 Very Bullish).
- Since the start of 2022, BioVie's shares were down around 55% , and over a period of one year, shares were down around 85% .
- Shares are currently +4.99% to $2.21 today.
For further details see:
BioVie initiated with an overweight at Cantor Fitzgerald